Graham Cooper

Graham Cooper has served as a member of Kezar Life Sciences Board of Directors since October 2017. Mr. Cooper served as Chief Financial Officer and Chief Operating Officer of Assembly Biosciences, Inc. from March 2018 until April 2019. Mr. Cooper served as the Chief Financial Officer of Receptos, Inc. from February 2013 until its sale to Celgene in August 2015 and Chief Financial Officer and Executive Vice President of Finance and Business Development at Geron Corporation from January 2012 to December 2012.

Prior to that, Mr. Cooper served as Chief Financial Officer of Orexigen Therapeutics, Inc. and held several positions at Deutsche Bank Securities, including Director, Health Care Investment Banking. Mr. Cooper also worked as an accountant at Deloitte & Touche LLP, where he earned his title CPA. Mr. Cooper has served as a member of the Board of Directors of Unity Biotechnology since August 2017, Applied Molecular Therapeutics, Inc. since January 2020, and Beam Therapeutics, Inc. since October 2019. Mr. Cooper previously served as a member of the board of Celladon Corporation.

Mr. Cooper received a B.A. degree in Economics from the University of California at Berkeley and an M.B.A. from the Stanford Graduate School of Business.